ws12 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Alomone Labs ws12
    Ws12, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ws12/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ws12 - by Bioz Stars, 2022-09
    93/100 stars
      Buy from Supplier

    ws12  (Tocris)
    92
    Tocris ws12
    Ws12, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ws12/product/Tocris
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ws12 - by Bioz Stars, 2022-09
    92/100 stars
      Buy from Supplier

    ws 12  (Abcam)
    92
    Abcam ws 12
    The biological effect of TRPM8 on esophageal cancer cells Colony formation assay was performed in EC109 cells with TRPM8 siRNA transfection ( A ), RQ-00203078 treatment ( B ), TRPM8 overexpression ( C ) and <t>WS</t> 12 treatment ( D ). Apoptosis of cells with TRPM8 siRNA transfection ( E ), RQ-00203078 treatment ( F ), TRPM8 overexpression ( G ) and WS 12 treatment ( H ) was measured by flow cytometry. ** P
    Ws 12, supplied by Abcam, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ws 12/product/Abcam
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ws 12 - by Bioz Stars, 2022-09
    92/100 stars
      Buy from Supplier

    Image Search Results


    The biological effect of TRPM8 on esophageal cancer cells Colony formation assay was performed in EC109 cells with TRPM8 siRNA transfection ( A ), RQ-00203078 treatment ( B ), TRPM8 overexpression ( C ) and WS 12 treatment ( D ). Apoptosis of cells with TRPM8 siRNA transfection ( E ), RQ-00203078 treatment ( F ), TRPM8 overexpression ( G ) and WS 12 treatment ( H ) was measured by flow cytometry. ** P

    Journal: Bioscience Reports

    Article Title: TRPM8 facilitates proliferation and immune evasion of esophageal cancer cells

    doi: 10.1042/BSR20191878

    Figure Lengend Snippet: The biological effect of TRPM8 on esophageal cancer cells Colony formation assay was performed in EC109 cells with TRPM8 siRNA transfection ( A ), RQ-00203078 treatment ( B ), TRPM8 overexpression ( C ) and WS 12 treatment ( D ). Apoptosis of cells with TRPM8 siRNA transfection ( E ), RQ-00203078 treatment ( F ), TRPM8 overexpression ( G ) and WS 12 treatment ( H ) was measured by flow cytometry. ** P

    Article Snippet: On the contrary, TRPM8 overexpression and WS 12, a selective TRPM8 agonist to augment Ca2+ influx [ ], facilitated cell viability ( K,L).

    Techniques: Colony Assay, Transfection, Over Expression, Flow Cytometry, Cytometry

    Aberrant expression of TRPM8 regulated cell viability of esophageal cancer cells The expression of TRPM8 in esophageal cancer samples and tissues adjacent to cancer by qRT-PCR (non-parametric t -test) ( A ) and Western blot ( B ). The mRNA level (non-parametric t -test) ( C ) and protein level ( D ) of TRPM8 in human esophageal epithelial cell line and human esophageal cancer cell lines. The mRNA level (non-parametric t -test) ( E ) and protein level ( F ) of TRPM8 in human normal cell lines and other human cancer cell lines. ( G ) The protein level of TRPM8 in esophageal cancer cells with TRPM8 siRNA transfection and RQ-00203078 treatment. Detection of cell viability in EC109 cells with TRPM8 siRNA transfection ( H ) and RQ-00203078 treatment ( I ) (two-way ANOVA). ( J ) The protein level of TRPM8 in esophageal cancer cells with TRPM8 overexpression and WS 12 treatment. Detection of cell viability in EC109 cells with TRPM8 overexpression ( K ) and WS 12 treatment ( L ) (two-way ANOVA). ** P

    Journal: Bioscience Reports

    Article Title: TRPM8 facilitates proliferation and immune evasion of esophageal cancer cells

    doi: 10.1042/BSR20191878

    Figure Lengend Snippet: Aberrant expression of TRPM8 regulated cell viability of esophageal cancer cells The expression of TRPM8 in esophageal cancer samples and tissues adjacent to cancer by qRT-PCR (non-parametric t -test) ( A ) and Western blot ( B ). The mRNA level (non-parametric t -test) ( C ) and protein level ( D ) of TRPM8 in human esophageal epithelial cell line and human esophageal cancer cell lines. The mRNA level (non-parametric t -test) ( E ) and protein level ( F ) of TRPM8 in human normal cell lines and other human cancer cell lines. ( G ) The protein level of TRPM8 in esophageal cancer cells with TRPM8 siRNA transfection and RQ-00203078 treatment. Detection of cell viability in EC109 cells with TRPM8 siRNA transfection ( H ) and RQ-00203078 treatment ( I ) (two-way ANOVA). ( J ) The protein level of TRPM8 in esophageal cancer cells with TRPM8 overexpression and WS 12 treatment. Detection of cell viability in EC109 cells with TRPM8 overexpression ( K ) and WS 12 treatment ( L ) (two-way ANOVA). ** P

    Article Snippet: On the contrary, TRPM8 overexpression and WS 12, a selective TRPM8 agonist to augment Ca2+ influx [ ], facilitated cell viability ( K,L).

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Transfection, Over Expression

    The cytotoxic effect of CD8 + T cells on esophageal cancer cells with genetic and pharmacological management Cell viability of co-incubation system containing CD8 + T cells and esophageal cancer cells with TRPM8 siRNA transfection ( A ), TRPM8 antagonist RQ-00203078 treatment ( B ), TRPM8 overexpression ( C ) and TRPM8 agonist WS 12 treatment ( D ) was assessed by CCK-8 assay. ( E ) Expression of PD-L1 in esophageal cancer cells with TRPM8 siRNA transfection and TRPM8 antagonist RQ-00203078 treatment. ( F ) Expression of PD-L1 in esophageal cancer cells with TRPM8 overexpression and TRPM8 agonist WS 12 treatment . * P

    Journal: Bioscience Reports

    Article Title: TRPM8 facilitates proliferation and immune evasion of esophageal cancer cells

    doi: 10.1042/BSR20191878

    Figure Lengend Snippet: The cytotoxic effect of CD8 + T cells on esophageal cancer cells with genetic and pharmacological management Cell viability of co-incubation system containing CD8 + T cells and esophageal cancer cells with TRPM8 siRNA transfection ( A ), TRPM8 antagonist RQ-00203078 treatment ( B ), TRPM8 overexpression ( C ) and TRPM8 agonist WS 12 treatment ( D ) was assessed by CCK-8 assay. ( E ) Expression of PD-L1 in esophageal cancer cells with TRPM8 siRNA transfection and TRPM8 antagonist RQ-00203078 treatment. ( F ) Expression of PD-L1 in esophageal cancer cells with TRPM8 overexpression and TRPM8 agonist WS 12 treatment . * P

    Article Snippet: On the contrary, TRPM8 overexpression and WS 12, a selective TRPM8 agonist to augment Ca2+ influx [ ], facilitated cell viability ( K,L).

    Techniques: Incubation, Transfection, Over Expression, CCK-8 Assay, Expressing

    TRPM8-calcineurin-NFATc3 signaling pathway contributed to PD-L1 expression in esophageal cancer cells The c alcineurin activity of esophageal cancer cells with TRPM8 siRNA transfection ( A ), TRPM8 antagonist RQ-00203078 treatment ( B ), TRPM8 overexpression ( C ) and TRPM8 agonist WS 12 treatment ( D ). Expression of p-NFATc3 and NFATc3 in esophageal cancer cells with TRPM8 inhibition ( E ) and TRPM8 activation ( F ). ( G ) Calcineurin activity of esophageal cancer cells with FK506 treatment. ( H ) Expression of PD-L1 and NFATc3 in cytoplasm and nucleus of esophageal cancer cells with FK506 treatment . *** P

    Journal: Bioscience Reports

    Article Title: TRPM8 facilitates proliferation and immune evasion of esophageal cancer cells

    doi: 10.1042/BSR20191878

    Figure Lengend Snippet: TRPM8-calcineurin-NFATc3 signaling pathway contributed to PD-L1 expression in esophageal cancer cells The c alcineurin activity of esophageal cancer cells with TRPM8 siRNA transfection ( A ), TRPM8 antagonist RQ-00203078 treatment ( B ), TRPM8 overexpression ( C ) and TRPM8 agonist WS 12 treatment ( D ). Expression of p-NFATc3 and NFATc3 in esophageal cancer cells with TRPM8 inhibition ( E ) and TRPM8 activation ( F ). ( G ) Calcineurin activity of esophageal cancer cells with FK506 treatment. ( H ) Expression of PD-L1 and NFATc3 in cytoplasm and nucleus of esophageal cancer cells with FK506 treatment . *** P

    Article Snippet: On the contrary, TRPM8 overexpression and WS 12, a selective TRPM8 agonist to augment Ca2+ influx [ ], facilitated cell viability ( K,L).

    Techniques: Expressing, Activity Assay, Transfection, Over Expression, Inhibition, Activation Assay